Amantadine: Clinical Trials

5 trials of Amantadine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 unknown. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 4, Unknown 1
Phase 22Completed 1, Unknown 1

Follow Amantadine: new trials by email Literature Review of Amantadine trials Research Report on Amantadine

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD - Influenza
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center72009-03-012013-08-15
Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine
amantadine hydrochloride, oseltamivir phosphate - Healthy
Phase 1CompletedNovartis182006-08-012007-11-30
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
Olanzapine, Amantadine, Olanzapine and placebo - Psychotic Disorder, Schizophreniform Disorder
Phase 1CompletedUniversity of North Carolina, Chapel Hill402005-05-012011-05-02
Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy
Amantadine - Hyperalgesia, Pain
Phase 1 / Phase 2UnknownUniversity Health Network, Toronto1322004-01-012006-03-14
Prepulse Inhibition of Startle in Cocaine Dependence - 7
Amantadine - Cocaine-Related Disorders, Substance-Related Disorders
Phase 1CompletedNational Institute on Drug Abuse (NIDA)1997-02-012017-01-12

Conditions studied

Cocaine-Related Disorders (1)  ·  Hyperalgesia (1)  ·  Influenza, Human (1)  ·  Pain (1)  ·  Prostatic Neoplasms (1)  ·  Psychotic Disorders (1)  ·  Schizophrenia (1)  ·  Substance-Related Disorders (1)

Sponsors

Fred Hutchinson Cancer Center (1)  ·  National Institute on Drug Abuse (NIDA) (1)  ·  Novartis (1)  ·  University Health Network, Toronto (1)  ·  University of North Carolina, Chapel Hill (1)

Countries

United States (4)  ·  Canada (1)

Top investigators

John Rotrosen, M.D. (1)  ·  Karen A Graham, MSc MD (1)  ·  Lucia Gagliese, PhD (1)  ·  Michael Boeckh, MD (1)

Results publications

PMID 18074029, PMID 23264438